The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. (Q54564143)

1 June 2018

meta-analysis

0 references

title

The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. (English)

1 reference

1 June 2018

main subject

meta-analysis

0 references

papillary thyroid cancer

1 reference

Eun Kyung Lee

5

0 references

Tae Yong Kim

object named as

Tae Hyuk Kim

1

0 references

Young Joo Park

object named as

Young Joo Park

2

0 references

author name string

Jung Ah Lim

3

1 reference

1 June 2018

Hwa Young Ahn

4

1 reference

1 June 2018

You Jin Lee

6

1 reference

1 June 2018

Kyung Won Kim

7

1 reference

1 June 2018

Seo Kyung Hahn

8

1 reference

1 June 2018

Yeo Kyu Youn

9

1 reference

1 June 2018

Kwang Hyun Kim

10

1 reference

1 June 2018

Bo Youn Cho

11

1 reference

1 June 2018

Do Joon Park

12

1 reference

1 June 2018

language of work or name

English

0 references

publication date

31 August 2011

1 reference

1 June 2018

published in

Cancer

1 reference

1 June 2018

volume

118

1 reference

1 June 2018

issue

7

1 reference

1 June 2018

page(s)

1764-1773

1 reference

1 June 2018

Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005.

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Thyroid cancer epidemiology and prognostic variables

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Prognostic utility of BRAF mutation in papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

BRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

BRAF mutations in an Italian cohort of thyroid cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Clinicopathological analysis of papillary thyroid cancer with PIK3CA alterations in a Middle Eastern population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

BRAF(V600E) mutation and outcome of patients with papillary thyroid carcinoma: a 15-year median follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

BRAF(V600E) mutation and the biology of papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

BRAF mutation in papillary thyroid carcinoma in a Japanese population: its lack of correlation with high-risk clinicopathological features and disease-free survival of patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

The prevalence and prognostic value of BRAF mutation in thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Lymphatic mapping establishes the role of BRAF gene mutation in papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto's thyroiditis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Molecular, morphologic, and outcome analysis of thyroid carcinomas according to degree of extrathyroid extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

BRAFV600E mutation in the pathogenesis of a large series of papillary thyroid carcinoma in Czech Republic

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

[Comments on the Ito et al. article (Endocr J. 2008 Oct 8. Epub ahead of print)] The lack of clinicopathological correlation of BRAF mutation in papillary thyroid cancer needs to be interpreted with caution.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Progression of BRAF-induced thyroid cancer is associated with epithelial-mesenchymal transition requiring concomitant MAP kinase and TGFβ signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

B-Raf(V600E) and thrombospondin-1 promote thyroid cancer progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Association of the T1799A BRAF mutation with tumor extrathyroidal invasion, higher peripheral platelet counts, and over-expression of platelet-derived growth factor-B in papillary thyroid cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Targeting BRAFV600E with PLX4720 displays potent antimigratory and anti-invasive activity in preclinical models of human thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Optimizing surgical treatment of papillary thyroid carcinoma associated with BRAF mutation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

The BRAFV600E mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Correlation Between Genetic Alterations and Microscopic Features, Clinical Manifestations, and Prognostic Characteristics of Thyroid Papillary Carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

7 January 2021

Prospective multicenter study of thyroiscarcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

7 January 2021

BRAF Mutation in Papillary Thyroid Carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

7 January 2021

Different structural components of conventional papillary thyroid carcinoma display mostly identical BRAF status

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

7 January 2021

BRAF Mutations in Papillary Thyroid Carcinomas Inhibit Genes Involved in Iodine Metabolism

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

7 January 2021

BRAF mutation and AKAP9 expression in sporadic papillary thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

7 January 2021

The oncogene BRAFV600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I− targeting to the membrane

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

7 January 2021

Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

7 January 2021

The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

7 January 2021

Clinicopathologic significance of BRAF V600E mutation in papillary carcinomas of the thyroid: a meta-analysis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26500

7 January 2021

Identifiers

DOI

10.1002/CNCR.26500

1 reference

1 June 2018

PubMed ID

21882184

1 reference

1 June 2018